8-K: Forte Biosciences Advances FB-102 Autoimmune Drug into Clinical Trials, Reports 2023 Financial Results

Forte Biosciences announced progress in its clinical-stage development of FB-102, a novel therapy for autoimmune diseases, alongside its year-end financial results.

Summary

• Forte Biosciences is advancing FB-102, a drug candidate for autoimmune diseases, into clinical trials.
• The company successfully completed the single ascending dose portion of the FB-102 phase 1 trial and has begun dosing in the multiple ascending dose cohorts.
• Research and development expenses for 2023 were $21.9 million, a significant increase from $5.6 million in 2022, primarily due to manufacturing and clinical trial costs.
• General and administrative expenses were $10.6 million in 2023, up from $8.3 million in 2022.
• Net losses per share were ($1.00) for 2023 and ($0.80) for 2022.
• Forte ended 2023 with approximately $37.1 million in cash and cash equivalents.
• As of December 31, 2023, Forte had approximately 36.3 million shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook for Forte Biosciences, highlighting the advancement of FB-102 into clinical trials and promising preclinical data. However, the company's financial losses and the need for additional capital temper the overall sentiment.

Positives

• FB-102 has shown promising preclinical results in multiple autoimmune disease models, including vitiligo, alopecia areata, and graft-versus-host disease.
• The successful completion of the SAD portion of the phase 1 trial and the initiation of the MAD cohorts represent significant progress in the clinical development of FB-102.
• FB-102 demonstrated significant survival benefits in a humanized mouse model of acute graft-versus-host disease, outperforming the standard of care, ruxolitinib.
• The combination therapy of FB-102 and ruxolitinib showed superior efficacy compared to ruxolitinib alone in preclinical studies.

Negatives

• Forte Biosciences reported a net loss of $31.476 million for the year ended December 31, 2023.
• Research and development expenses increased significantly in 2023 compared to 2022 due to the advancement of FB-102 into clinical trials.

Risks

• Forte may need to obtain additional capital to continue advancing FB-102.
• Clinical trials may face delays in commencement, enrollment, or completion.
• Preclinical results may not be indicative of clinical trial outcomes.
• There is a risk that FB-102 may not be successfully brought to market due to inherent difficulties in drug development.

Future Outlook

Forte Biosciences plans to provide further clinical updates on FB-102 throughout the year.

Management Comments

• Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences, stated, 'Forte achieved a major milestone by advancing FB-102 into the clinic and beating the timelines we targeted in our third quarter business update.'
• 'The single ascending dose (SAD) portion of the FB-102 phase 1 trial was successfully completed and dosing has begun in the multiple ascending dose (MAD) cohorts.'
• 'I am deeply appreciative of the talented Forte team that made this achievement possible.'
• 'I also want to thank our investors who believe in the potential of FB-102 and in the Forte team as we continue to advance this exciting program.'
• 'We look forward to providing more clinical updates on FB-102 over the course of this year.'

Industry Context

The development of FB-102 addresses a significant unmet need in the treatment of autoimmune diseases, particularly vitiligo and alopecia areata, where current treatments have limitations. The global vitiligo treatment market is projected to reach $1.9 billion by 2026, and the global alopecia treatment market is projected to reach $3.9 billion by 2026.

Comparison to Industry Standards

• In preclinical studies, FB-102 demonstrated a 90% survival rate in a humanized mouse model of acute graft-versus-host disease, comparable to the 90% survival rate observed with Incyte's ruxolitinib, which achieved a 62% overall response rate at Day 28 in a commercial setting.
• Equillium/Ono's itolizumab showed a 50% survival rate in a similar model and achieved a greater than 50% overall response rate in a Phase 3 trial.
• Incyte's itacitinib, another JAK 1 inhibitor, showed a 20% survival rate in the same model but was terminated in a Phase 3 trial due to not being statistically significant versus placebo.
• These comparisons suggest that FB-102's preclinical efficacy is promising and potentially superior to some existing or investigational treatments for acute graft-versus-host disease.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if FB-102 is successful in clinical trials and commercialization.
• Employees: Continued employment and potential for growth as the company advances its clinical programs.
• Patients: Potential for a new and effective treatment option for autoimmune diseases such as graft-versus-host disease, vitiligo, and alopecia areata.

Next Steps

• Forte Biosciences will continue with the multiple ascending dose (MAD) cohorts of the FB-102 phase 1 trial.
• The company will provide further clinical updates on FB-102 throughout the year.

Key Dates

Keywords

FB-102, Forte Biosciences, autoimmune diseases, clinical trials, graft-versus-host disease, vitiligo, alopecia areata, CD122, immunotherapy, biopharmaceutical, ruxolitinib, preclinical data, phase 1 trial